BiotechTube

Everolimus + Tacrolimus + Mycophenolic acid

ApprovedUNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Kidney; Complications, Allograft

Conditions

Kidney; Complications, Allograft

Trial Timeline

Mar 1, 2013 → Dec 1, 2015

NCT ID
NCT02036554

About Everolimus + Tacrolimus + Mycophenolic acid

Everolimus + Tacrolimus + Mycophenolic acid is a approved stage product being developed by Novartis for Kidney; Complications, Allograft. The current trial status is unknown. This product is registered under clinical trial identifier NCT02036554. Target conditions include Kidney; Complications, Allograft.

What happened to similar drugs?

20 of 20 similar drugs in Kidney; Complications, Allograft were approved

Approved (20) Terminated (1) Active (0)
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅TacrolimusAstellas PharmaApproved
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
✅Tacrolimus granulesAstellas PharmaApproved
✅Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + CorticosteroidsAstellas PharmaApproved
✅MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved
✅Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02036554ApprovedUNKNOWN

Competing Products

20 competing products in Kidney; Complications, Allograft

See all competitors
ProductCompanyStageHype Score
Empagliflozin + Matching placeboEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 2
35
SGLT2 inhibitorEli LillyPre-clinical
30
LY2623091 + EplerenoneEli LillyPhase 2
35
Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
39
TacrolimusAstellas PharmaApproved
35
RituximabAstellas PharmaPhase 2
35
Prograf + MR4Astellas PharmaPhase 3
40
basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
43
Tacrolimus, modified releaseAstellas PharmaPhase 3
40
Tacrolimus granulesAstellas PharmaApproved
43
roxadustatAstellas PharmaPhase 3
40
Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + CorticosteroidsAstellas PharmaApproved
43
ASP1128 + PlaceboAstellas PharmaPhase 2
35
FK506MR + Prograf + Mycophenolate Mofetil + Methylprednisolone + PrednisoloneAstellas PharmaPhase 3
40
MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved
43
ASP1585Astellas PharmaPhase 3
40
Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + CorticosteroidsAstellas PharmaPhase 2
35
Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved
43
tacrolimusAstellas PharmaApproved
39